Stryker Corporation (SYK) Q4 2025 Financial Results Summary

Stryker (SYK) Q4 2025 Financial Results Summary

Portage, Michigan – January 29, 2026 – Stryker (NYSE:SYK) reported its operating results for the fourth quarter and full year of 2025. Below is a summary of the key financial metrics and results.

Fourth Quarter Results

• Net Sales Growth:
• Reported net sales increased 11.4% to $7.2 billion.

• Organic net sales grew by 11.0%.

• Operating Income & Margins:

• Reported operating income margin was 25.2%.

• Adjusted operating income margin increased by 100 basis points to 30.2%.

• Earnings Per Share (EPS):

• Reported EPS surged 56.0% to $2.20.

• Adjusted EPS increased by 11.5% to $4.47.

• Segment Performance:

• MedSurg and Neurotechnology:
  • Net sales of $4.6 billion, up 17.5%. Organic growth of 12.6%.
• Orthopaedics:
  • Net sales of $2.6 billion, an increase of 2.2%. Organic growth of 8.4%.

Full Year Results

• Net Sales:
• Total net sales for 2025 were $25.1 billion, representing an increase of 11.2%.

• Organic net sales rose by 10.3%.

• Operating Margins:

• Reported operating income margin for the year was 19.5%.

• Adjusted operating income margin increased by 100 basis points to 26.3%.

• Earnings:

• Reported net earnings were $3.2 billion, growing 8.5%.
• Reported EPS for the year reached $8.40, up 8.2%.

• Adjusted EPS was $13.63, marking an increase of 11.8%.

• Segment Performance:

• MedSurg and Neurotechnology:
  • Sales of $15.6 billion, growing 15.7%. Organic growth was 10.7%.
• Orthopaedics:
  • Sales totaled $9.5 billion, up 4.3%. Organic growth reached 9.5%.

Additional Information

• Cash Flow:
• Net cash provided by operating activities was $5.0 billion, compared to $4.2 billion in 2024.
• Net cash used in investing activities totaled -$4.9 billion.

• Cash dividends paid were $1.284 billion, an increase compared to $1.219 billion in 2024.

• Share Repurchase Program: No share repurchase program was mentioned in the report.

• 2026 Outlook:

• Projected organic net sales growth for 2026 is expected to be in the range of 8.0% to 9.5%.
• Expected adjusted net earnings per diluted share is forecasted between $14.90 and $15.10.

Highlights

• Strong Demand & Momentum:

• The company reported considerable growth driven by a robust pipeline in MedTech, increasing procedural volumes, and strong demand for capital products.

• Market Positioning:

• Stryker has positioned itself for continued success, having exceeded $25 billion in revenue during the year.

Stryker’s successful financial results showcase its capability to navigate challenges while capitalizing on opportunities within the healthcare sector, setting a solid foundation for future growth.